聚乙二醇化重组人粒细胞刺激因子致白细胞增多的国内外文献分析
|
摘要
目的:分析聚乙二醇化重组人粒细胞刺激因子致白细胞增多的临床情况及特点,为临床实践提供依据及建议。方法:采用文献回顾性研究方法,对聚乙二醇化重组人粒细胞刺激因子致白细胞增多患者的临床资料进行统计分析。结果:共纳入文献13篇,涉及患者545例次。聚乙二醇化重组人粒细胞刺激因子致白细胞增多时,用药剂量以固定剂量6mg为主,兼有30,60,100,150,200μg·kg-1或固定剂量12mg,用药途径为皮下注射,不良反应发生于给药后1～11d,WBC范围为(10～230)×109·L-1。多数患者不用特殊处理,有3例需要处理的手段包括水化、血浆分离术等。结论:临床应用聚乙二醇化重组人粒细胞刺激因子时应加强用药监测,以避免和减少白细胞过高的发生。
OBJECTIVE To analyze the clinical patterns and characteristics of leukocytosis induced by pegfilgrastim and provide the reference for clinical medication.METHODS Medical records of the leukocytosis induced by pegfilgrastim were summarized and analyzed.RESULTS A total of 13 literatures were included involving 545 ADRs.When leukocytosis happened,the main dosage of pegfilgrastim was 6 mg,including 30,60,100,150,200μg·kg-1 or a fixed dose of 12 mg,leukocytosis was observed usually 1-11 days after pegfilgrastim was administered subcutaneously.Most patients didn't need extra treatment,but 3 cases were treated by hydration or leukopheresis.CONCLUSION Drug monitoring should be enhanced when pegfilgrastim is used,to avoid and reduce the incidences of exorbitant leukocytosis.
OBJECTIVE To analyze the clinical patterns and characteristics of leukocytosis induced by pegfilgrastim and provide the reference for clinical medication.METHODS Medical records of the leukocytosis induced by pegfilgrastim were summarized and analyzed.RESULTS A total of 13 literatures were included involving 545 ADRs.When leukocytosis happened,the main dosage of pegfilgrastim was 6 mg,including 30,60,100,150,200μg·kg-1 or a fixed dose of 12 mg,leukocytosis was observed usually 1-11 days after pegfilgrastim was administered subcutaneously.Most patients didn't need extra treatment,but 3 cases were treated by hydration or leukopheresis.CONCLUSION Drug monitoring should be enhanced when pegfilgrastim is used,to avoid and reduce the incidences of exorbitant leukocytosis.
引文
[1]Molineux G.Pegylation:engineering improved pharmaceuticals for enhanced therapy[J].Cancer Treat Rev,2002,28(Suppl A):13-16.
[2] Lokich J.Same-day pegfilgrastim and chemotherapy[J].Cancer Invest,2005,23(7):573-576.
[3] Draper BK,Robbins JB,Stricklin GP.Bullous Sweet's syndrome in congenital neutropenia:association with pegfilgrastim[J].J Am Acad Dermatol,2005,52(5):901-905.
[4] Arshad M,Seiter K,Bilaniuk J,et al.Side effects related to cancer treatment:CASE 2.Splenic rupture following pegfilgrastim[J].J Clin Oncol,2005,23(33):8533-8534.
[5] Wolff AC,Jones RJ,Davidson NE,et al.Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support[J].J Clin Oncol,2006,24(15):2392-2394.
[6] Raez LE,Santos ES,Lopes G,et al.Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer(NSCLC)[J].Lung Cancer,2006,53(3):347-353.
[7] Snyder RL,Stringham DJ.Pegfilgrastim-induced hyperleukocytosis[J].Ann Pharmacother,2007,41(9):1524-1530.
[8] Heydrich BN,Schoch R,Horst HA,et al.Dramatic hyperleukocytosis after treatment of myelodysplastic syndrome with pegfilgrastim and darbepoetin-alfa[J].Ann Hematol,2008,87(1):77-78.
[9] Perez FA,Fligner CL,Yu EY.Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder:possible effect of granulocyte colony-stimulating factor[J].J Clin Oncol,2009,27(34):e215-e217.
[10]Hecht JR,Pillai M,Gollard R,et al.A randomized,placebocontrolled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy[J].Clin Colorectal Cancer,2010,9(2):95-101.
[11]Manzoni M,Delfanti S,Rovati B,et al.Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastimsupported dose-dense regimens[J].Clin Exp Med,2010,10(2):135-138.
[12]Herbert KE,Gambell P,Link EK,et al.Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells[J].Bone Marrow Transplant,2013,48(3):351-356.
[13]Sun CC,Wang BC,Bi JW,et al.Phase I clinical trial tolerance of pegylated recombinant human granulocyte colony-stimulating factor injection[J].Chin J Clin Pharmacol Ther(中国临床药理学与治疗学),2013,18(3):302-306.
[14]Lambertini M,Bruzzi P,Poggio F,et al.Pegfilgrastim administration after 24or 72or 96hto allow dose-dense anthracycline-and taxane-based chemotherapy in breast cancer patients:a single-center experience within the GIM2randomized phase III trial[J].Support Care Cancer,2016,24(3):1285-1294.
[15]Koulis TA,Kornaga EN,Banerjee R,et al.Anemia,leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy:A retrospective cohort study[J].Clin Transl Radiat Oncol,2017,12(4):51-56.
[16]Vacirca JL,Chan A,Mezei K,et al.An open-label,dose-ranging study of Rolontis,a novel long-acting myeloid growth factor,in breast cancer[J].Cancer Med,2018 Mar 23.doi:10.1002/cam4.1388.
[17]Yang BB,Kido A.Pharmacokinetics and pharmacodynamics of pegfilgrastim[J].Clin Pharmacokinet,2011,50(5):295-306.
[18]Usami E,Kimura M,Iwai M,etal.The incidence and timing of leukocyte overshoot after pegfilgrastim administration[J].J Oncol Pharm Pract,2018Jan 1.doi:10.1177/1078155218769140.
[19]Weycker D,Bensink M,Lonshteyn A,etal.Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010to 2015[J].Curr Med Res Opin,2017,33(12):2107-2113.
[20]Donkor KN,Selim JH,Waworuntu A,etal.Safety and Efficacy of Pegfilgrastim When Given Less Than 14Days Before the Next Chemotherapy Cycle:Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion[J].Ann Pharmacother,2017,51(10):840-847.
[21]Pala C,Mumcuoglu H,Kurnaz F,et al.Changes in CD34+cell count in peripheral blood after whole blood donation[J].Transfus Apher Sci,2013,49(2):259-262.
[22]Amgen Inc.Neulasta(package insert).Thousand Oaks,CA:Amgen Inc,2017.
[2] Lokich J.Same-day pegfilgrastim and chemotherapy[J].Cancer Invest,2005,23(7):573-576.
[3] Draper BK,Robbins JB,Stricklin GP.Bullous Sweet's syndrome in congenital neutropenia:association with pegfilgrastim[J].J Am Acad Dermatol,2005,52(5):901-905.
[4] Arshad M,Seiter K,Bilaniuk J,et al.Side effects related to cancer treatment:CASE 2.Splenic rupture following pegfilgrastim[J].J Clin Oncol,2005,23(33):8533-8534.
[5] Wolff AC,Jones RJ,Davidson NE,et al.Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support[J].J Clin Oncol,2006,24(15):2392-2394.
[6] Raez LE,Santos ES,Lopes G,et al.Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer(NSCLC)[J].Lung Cancer,2006,53(3):347-353.
[7] Snyder RL,Stringham DJ.Pegfilgrastim-induced hyperleukocytosis[J].Ann Pharmacother,2007,41(9):1524-1530.
[8] Heydrich BN,Schoch R,Horst HA,et al.Dramatic hyperleukocytosis after treatment of myelodysplastic syndrome with pegfilgrastim and darbepoetin-alfa[J].Ann Hematol,2008,87(1):77-78.
[9] Perez FA,Fligner CL,Yu EY.Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder:possible effect of granulocyte colony-stimulating factor[J].J Clin Oncol,2009,27(34):e215-e217.
[10]Hecht JR,Pillai M,Gollard R,et al.A randomized,placebocontrolled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy[J].Clin Colorectal Cancer,2010,9(2):95-101.
[11]Manzoni M,Delfanti S,Rovati B,et al.Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastimsupported dose-dense regimens[J].Clin Exp Med,2010,10(2):135-138.
[12]Herbert KE,Gambell P,Link EK,et al.Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells[J].Bone Marrow Transplant,2013,48(3):351-356.
[13]Sun CC,Wang BC,Bi JW,et al.Phase I clinical trial tolerance of pegylated recombinant human granulocyte colony-stimulating factor injection[J].Chin J Clin Pharmacol Ther(中国临床药理学与治疗学),2013,18(3):302-306.
[14]Lambertini M,Bruzzi P,Poggio F,et al.Pegfilgrastim administration after 24or 72or 96hto allow dose-dense anthracycline-and taxane-based chemotherapy in breast cancer patients:a single-center experience within the GIM2randomized phase III trial[J].Support Care Cancer,2016,24(3):1285-1294.
[15]Koulis TA,Kornaga EN,Banerjee R,et al.Anemia,leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy:A retrospective cohort study[J].Clin Transl Radiat Oncol,2017,12(4):51-56.
[16]Vacirca JL,Chan A,Mezei K,et al.An open-label,dose-ranging study of Rolontis,a novel long-acting myeloid growth factor,in breast cancer[J].Cancer Med,2018 Mar 23.doi:10.1002/cam4.1388.
[17]Yang BB,Kido A.Pharmacokinetics and pharmacodynamics of pegfilgrastim[J].Clin Pharmacokinet,2011,50(5):295-306.
[18]Usami E,Kimura M,Iwai M,etal.The incidence and timing of leukocyte overshoot after pegfilgrastim administration[J].J Oncol Pharm Pract,2018Jan 1.doi:10.1177/1078155218769140.
[19]Weycker D,Bensink M,Lonshteyn A,etal.Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010to 2015[J].Curr Med Res Opin,2017,33(12):2107-2113.
[20]Donkor KN,Selim JH,Waworuntu A,etal.Safety and Efficacy of Pegfilgrastim When Given Less Than 14Days Before the Next Chemotherapy Cycle:Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion[J].Ann Pharmacother,2017,51(10):840-847.
[21]Pala C,Mumcuoglu H,Kurnaz F,et al.Changes in CD34+cell count in peripheral blood after whole blood donation[J].Transfus Apher Sci,2013,49(2):259-262.
[22]Amgen Inc.Neulasta(package insert).Thousand Oaks,CA:Amgen Inc,2017.